The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis

Znanstveni rad - Prikaz slučaja

• Autor: Vesna Bišof
• Autor: Matea Zajc Petranović
• Autor: Zoran Rakušić
• Autor: Kristina Ruža Samardžić
• Autor: Antonio Juretić
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti

Sažetak (engleski)

Excision repair cross-complementation group 1 (ERCC1) protein has been extensively investigated as a prognostic and predictive factor for platinum-based treatment in head and neck squamous cell carcinoma (HNSCC) but with inconsistent results. We performed the present meta-analysis to better elucidate this issue in advanced HNSCC. A literature search was conducted using the PubMed and Web of Science databases. The inclusion criteria were head and neck cancer patients with platinum-based treatment and evaluation of the correlation between ERCC1 expression and clinical outcomes [objective response rate (ORR), progression-free survival (PFS), and overall survival (OS), both unadjusted and adjusted estimates]. In high vs. low pooled analyses, high ERCC1 expression was associated with unfavorable OS [hazard ratio (HR) = 1.95, 95 % confidence interval (CI) 1.18-3.21, p = 0.009], PFS (HR = 2.39, 95 % CI 1.74-3.28, p = 0.000) and ORR (odds ratio = 0.48, 95 % CI 0.23-0.98, p = 0.044). In the subgroup analysis of adjusted OS estimates, ERCC1 was a predictor of shorter survival in Asians (HR = 3.13, 95 % CI 2.09-4.70, p = 0.000) and Caucasians (HR = 2.02, 95 % CI 1.32-3.07, p = 0.001) but of longer survival in South Americans (HR = 0.17, 95 % CI 0.07-0.40, p = 0.000). Immunohistochemistry proved to be of predictive value irrespective of used antibody (p = 0.009). In the stratified analysis according to the tumor site, ERCC1 expression was associated with OS in nasopharyngeal cancer (HR = 2.72, 95 % CI 1.79-4.13, p = 0.000). ERCC1 has a potential to become predictive and prognostic factor enabling treatment tailoring in HNSCC patients.

• Ključne riječi (engleski): Antineoplastic Agents/therapeutic use; Carcinoma, Squamous Cell/diagnosis; Carcinoma, Squamous Cell/drug therapy; Carcinoma, Squamous Cell/metabolism; DNA Repair; DNA-Binding Proteins/metabolism; Disease-Free Survival; Endonucleases/metabolism; Head and Neck Neoplasms/diagnosis; Head and Neck Neoplasms/drug therapy; Head and Neck Neoplasms/metabolism; Humans; Platinum Compounds/therapeutic use; Predictive Value of Tests; Prognosis; Proportional Hazards Models
• Jezik: engleski
• Vrsta publikacije: Znanstveni rad - Prikaz slučaja
• Status objave: Objavljen
• Vrsta recenzije: Recenziran
• Verzija publikacije: Završna verzija rukopisa prihvaćena za objavljivanje (postprint)
• Naslov časopisa: European Archives of Oto-Rhino-Laryngology
• Brojčani podaci: vol. 273, br. 9, str. 2305-2317
• p-ISSN: 0937-4477
• DOI: https://doi.org/10.1007/s00405-015-3710-x
• URN:NBN: urn:nbn:hr:105:486557
• Datum objave publikacije: 2016-09
• URL dokumenta: https://doi.org/10.1007/s00405-015-3710-x
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2024-03-28 08:53:21